This site is intended for healthcare professionals

Logo Scientific Seminars
CME & Education Platform

CLINICAL UPDATES IN ADVANCEMENTS OF TREATMENT OF TNBC, HR+,HER2+, HER2-LOW, BREAST CANCER: ESMO CONGRESS UPDATES

Oncology

Educational Activities  

| Overview

| Language

| Learning Objectives

| Target Audience

Go to E-Platform

Educational Activities

  • ONLINE COURSE
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Italy
Self Study Module 2 - Antibody Drug Conjugates - Italy
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Germany
Self Study Module 2 - Antibody Drug Conjugates - Germany
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - France
Self Study Module 2 - Antibody Drug Conjugates - France
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Japan
Self Study Module 2 - Antibody Drug Conjugates - Japan
Self Study Module 1 -Defining the therapeutic algorithm in patients with HR positive breast cancer - Defining the therapeutic algorithm in patients with HR positive breast cancer- US
Self Study Module 2 - Antibody Drug Conjugates - US
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Spain
Self Study Module 2 - Antibody Drug Conjugates - Spain
  • Highlights Video

Go to E-Platform

– Overview

– Language

– Learning Objectives

– Target Audience

– E-Learning Activities

  • Overview

The aim of this educational curriculum is to present and evaluate latest breakthroughs, therapies, and strategies in Breast Cancer (BC) management that have transformed the approach to this complex and chronic condition. The two self-study modules are designed to offer a thorough understanding of the wide range of treatment modalities available. From conventional methods to cutting-edge innovations, providing insights on BC management optimization, including the use of Antibody Drug Conjugates (ADCs), immunotherapy, Parp-inhibitors and a potential therapeutic algorithm for HER2-low breast cancer.

Endorsed by

 

   

  • Educational Activities
  • Learning Objectives
  • Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globally
  • Apply the most recent evidence-based recommendations when managing patients with HR+ and BRCAm+ BC, based on specific patient and tumor characteristics
  • Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of treatment optimization for HR+/HER2- breast cancer
  • Target Audience

Oncology clinicians and specifically those actively involved in the treatment of breast cancer.

 

 

 

 

 

 

 

A collaboration between Scientific Seminars International Foundation and AXDEV Global Inc. in Join Providership with RealCME and Academic CME

  • Language

English

  • Continuing Medical Education
  • Medical Advisor
  • Faculty
Gligorov Joseph
Biografia
Bhattacharya Saveri
Biografia
Sanchez Katherine
Biografia
Maes-Carballo Marta
Biografia
Niikura Naoki
Biografia
Sawaki​ Masataki
Biografia
Kolberg Hans-Christian
Biografia
Grinda Thomas
Biografia
Riedel Fabian
Biografia
Lambertini Matteo
Biografia
Gligorov Joseph
Bhattacharya Saveri
Sanchez Katherine
Maes-Carballo Marta
Niikura Naoki
Sawaki​ Masataki
Kolberg Hans-Christian
Grinda Thomas
Riedel Fabian
Lambertini Matteo

Share it on social

Download Flyer
Go to E-Platform
Download Flyer

EDUCATIONAL RESOURCES

  • SLIDE KITS
  • VIDEO LECTURES
  • SCIENTIFIC HIGHLIGHTS
  • VIDEO INTERVIEW
  • ONLINE COURSE
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Italy
Self Study Module 2 - Antibody Drug Conjugates - Italy
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Germany
Self Study Module 2 - Antibody Drug Conjugates - Germany
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - France
Self Study Module 2 - Antibody Drug Conjugates - France
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Japan
Self Study Module 2 - Antibody Drug Conjugates - Japan
Self Study Module 1 -Defining the therapeutic algorithm in patients with HR positive breast cancer - Defining the therapeutic algorithm in patients with HR positive breast cancer- US
Self Study Module 2 - Antibody Drug Conjugates - US
Self Study Module 1 - Defining the therapeutic algorithm in patients with HR positive breast cancer - Spain
Self Study Module 2 - Antibody Drug Conjugates - Spain
  • Virtual Animated Conversation
  • CONGRESS REPORT
  • ARTICLE

For additional information please contact: info@scientificseminars.com

This educational program is made possible thanks to an independent educational grant received from Daiichi Sankyo, Inc.

 

 

Other activities

Scientific Seminars Foundation